TAMPA, Fla.--(BUSINESS WIRE)--Accentia Biopharmaceuticals, Inc. (NASDAQ: ABPI) notes that its
consolidated financial statements for the fiscal year ended September
30, 2006, including its majority-owned subsidiary Biovest International,
were audited by Aidman Piser & Co., which issued its opinion and
continued the going concern disclaimer. The 2006 disclaimer is
consistent with the Company’s 2004 and 2005
financial statements, which reflects the continued developmental stage
of Accentia's consolidated business with Biovest. This information was
accurately disclosed in the Company's Form 10-K filed on December 29,
2006.
About Accentia Biopharmaceuticals, Inc.
Accentia Biopharmaceuticals, Inc. is a biopharmaceutical company focused
on the development of late-stage "disruptive" clinical products.
Accentia has a portfolio of currently marketed respiratory products and
a pipeline of products in clinical development. The company's lead
respiratory product candidate is SinuNase(TM), which is under clinical
development to treat chronic sinusitis (rhinosinusitis). SinuNase is a
novel application and formulation of a known anti-fungal exclusively
licensed from the Mayo Foundation for Medical Education and Research.
The product has been Fast Tracked by the FDA and the Company has
commenced a Phase 3 clinical trial. The Company's other lead product is
BiovaxID(TM), a patient-specific anti-cancer vaccine for the treatment
of follicular non-Hodgkin's lymphoma. BiovaxID, which is being developed
by Accentia's subsidiary Biovest International, Inc., (OTCBB:BVTI) is
currently in a Fast-Tracked Phase 3 clinical trial. Additionally, the
Company has a family of respiratory specialty pharmaceutical products,
including MD Turbo(TM), an FDA approved, commercially available product
that transforms over 90% of dispensed metered-dose inhalers into a
breath-activated, dose-counting inhaler. For further information, please
visit www.accentia.net.
